Curaxin CBL0137, a structural analog of 9-aminoacridine, is another small-molecule YAP inhibitor that plays the same role and is expected to become a new drug for the treatment of atherosclerosis (Ding et al., 2023). The gene discussed is YAP1; the disease is atherosclerosis.